Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.67 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.66 |
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775624 | 1.00 | DPP8 (0.67) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL4771240 | 0.86 | HDAC8 (0.57) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL4900688 | 0.86 | HDAC8 (0.57) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL4776344 | 0.81 | DPP8 (0.65) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL4911662 | 0.81 | DPP8 (0.65) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL20570474 | 0.80 | HDAC8 (0.69) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL28997417 | 0.80 | DPP7 (1.00) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL31653974 | 0.80 | DPP7 (1.00) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL21746926 | 0.80 | DPP7 (1.00) | DPP8DPP7DPP9HDAC8DPP4 | |
| SCHEMBL14523899 | 0.80 | DPP4 (0.71) | DPP8DPP7DPP9HDAC8DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101282932-A | Carboxyamine compounds and their use in the treatment of HDAC dependent diseases | NOVARTIS AG (CH) | 2008-10-08 | — | — | CN | claimed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | DPP8 1164/4885DPP7 921/4885DPP9 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.